At 11:10 am on Thursday, Glenmark Pharma shares reached an all-time high of Rs 1,883.00 on the NSE, currently trading at Rs 1,878.40, a gain of 3.28% from the previous close. The stock is also trading among the top gainers on the Nifty Midcap 150.
Here's a look at Glenmark Pharma's financial performance:
The following table presents the consolidated quarterly financials for Glenmark Pharma:
| Heading | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 3,062.95 Crore | Rs 3,244.19 Crore | Rs 3,433.80 Crore | Rs 3,387.55 Crore | Rs 3,256.21 Crore |
| Net Profit | -Rs 1,214.27 Crore | Rs 340.24 Crore | Rs 354.49 Crore | Rs 348.03 Crore | Rs 4.38 Crore |
| EPS | -43.18 | 12.06 | 12.55 | 12.33 | 0.16 |
The revenue for the quarter ending March 2025 stood at Rs 3,256.21 Crore, compared to Rs 3,062.95 Crore in March 2024. The net profit for the same period was Rs 4.38 Crore, a significant increase from the net loss of Rs 1,214.27 Crore in March 2024.
The following table presents the consolidated yearly financials:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 10,943.93 Crore | Rs 12,304.90 Crore | Rs 12,990.11 Crore | Rs 11,813.10 Crore | Rs 13,321.74 Crore |
| Net Profit | Rs 970.09 Crore | Rs 993.65 Crore | Rs 377.40 Crore | -Rs 1,830.85 Crore | Rs 1,047.14 Crore |
| EPS | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 |
| BVPS | 250.36 | 334.48 | 348.70 | 278.09 | 313.60 |
| ROE | 13.73 | 10.36 | 3.13 | -19.13 | 11.83 |
| Debt to Equity | 0.66 | 0.40 | 0.46 | 0.13 | 0.25 |
The annual revenue for 2025 increased to Rs 13,321.74 Crore from Rs 11,813.10 Crore in 2024. The net profit also saw a significant recovery, reaching Rs 1,047.14 Crore in 2025 compared to a loss of Rs 1,830.85 Crore in 2024.
The following table shows the income statement for the past five years:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | Rs 13,321 Crore | Rs 11,813 Crore | Rs 12,990 Crore | Rs 12,304 Crore | Rs 10,943 Crore |
| Other Income | Rs 113 Crore | Rs 839 Crore | Rs 316 Crore | Rs 166 Crore | Rs 50 Crore |
| Total Income | Rs 13,435 Crore | Rs 12,653 Crore | Rs 13,306 Crore | Rs 12,471 Crore | Rs 10,994 Crore |
| Total Expenditure | Rs 11,829 Crore | Rs 12,100 Crore | Rs 12,088 Crore | Rs 10,732 Crore | Rs 9,258 Crore |
| EBIT | Rs 1,606 Crore | Rs 552 Crore | Rs 1,218 Crore | Rs 1,739 Crore | Rs 1,735 Crore |
| Interest | Rs 207 Crore | Rs 515 Crore | Rs 349 Crore | Rs 298 Crore | Rs 353 Crore |
| Tax | Rs 352 Crore | Rs 1,867 Crore | Rs 491 Crore | Rs 447 Crore | Rs 412 Crore |
| Net Profit | Rs 1,047 Crore | -Rs 1,830 Crore | Rs 377 Crore | Rs 993 Crore | Rs 970 Crore |
The following table shows the cash flow from the year 2021 to 2025:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | -Rs 827 Crore | -Rs 265 Crore | Rs 625 Crore | Rs 1,108 Crore | Rs 1,131 Crore |
| Investing Activities | Rs 2 Crore | Rs 4,560 Crore | -Rs 528 Crore | -Rs 333 Crore | -Rs 675 Crore |
| Financing Activities | Rs 787 Crore | -Rs 3,906 Crore | -Rs 77 Crore | -Rs 520 Crore | -Rs 441 Crore |
| Others | Rs 55 Crore | -Rs 174 Crore | Rs 13 Crore | Rs 17 Crore | Rs 13 Crore |
| Net Cash Flow | Rs 17 Crore | Rs 215 Crore | Rs 32 Crore | Rs 272 Crore | Rs 27 Crore |
The following table displays the balance sheet data:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | Rs 28 Crore | Rs 28 Crore | Rs 28 Crore | Rs 28 Crore | Rs 28 Crore |
| Reserves & Surplus | Rs 8,821 Crore | Rs 7,801 Crore | Rs 9,445 Crore | Rs 9,058 Crore | Rs 7,036 Crore |
| Current Liabilities | Rs 5,967 Crore | Rs 5,818 Crore | Rs 5,045 Crore | Rs 4,689 Crore | Rs 4,201 Crore |
| Other Liabilities | Rs 1,233 Crore | Rs 710 Crore | Rs 4,852 Crore | Rs 3,307 Crore | Rs 4,337 Crore |
| Total Liabilities | Rs 16,049 Crore | Rs 14,358 Crore | Rs 19,371 Crore | Rs 17,083 Crore | Rs 15,603 Crore |
| Fixed Assets | Rs 5,251 Crore | Rs 4,804 Crore | Rs 7,380 Crore | Rs 6,837 Crore | Rs 6,452 Crore |
| Current Assets | Rs 9,295 Crore | Rs 7,428 Crore | Rs 9,873 Crore | Rs 8,282 Crore | Rs 7,359 Crore |
| Other Assets | Rs 1,502 Crore | Rs 2,125 Crore | Rs 2,117 Crore | Rs 1,963 Crore | Rs 1,791 Crore |
| Total Assets | Rs 16,049 Crore | Rs 14,358 Crore | Rs 19,371 Crore | Rs 17,083 Crore | Rs 15,603 Crore |
| Contingent Liabilities | Rs 0 Crore | Rs 1,193 Crore | Rs 477 Crore | Rs 559 Crore | Rs 544 Crore |
Key financial ratios for Glenmark Pharma are as follows:
| Ratio | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 |
| Diluted EPS (Rs.) | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 |
| Book Value / Share (Rs.) | 250.36 | 334.48 | 348.70 | 278.09 | 313.60 |
| Dividend / Share (Rs.) | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 |
| Face Value | 1 | 1 | 1 | 1 | 1 |
| Gross Profit Margin (%) | 19.50 | 20.21 | 19.97 | 17.22 | 18.50 |
| Operating Margin (%) | 15.45 | 16.25 | 15.27 | 12.30 | 14.85 |
| Net Profit Margin (%) | 8.86 | 8.07 | 2.90 | -12.13 | 7.86 |
| Return on Equity (%) | 13.73 | 10.36 | 3.13 | -19.13 | 11.83 |
| ROCE (%) | 14.83 | 16.13 | 13.84 | 17.01 | 19.62 |
| Return On Assets (%) | 6.21 | 5.51 | 1.53 | -10.45 | 6.52 |
| Current Ratio (X) | 1.75 | 1.77 | 1.96 | 1.28 | 1.56 |
| Quick Ratio (X) | 1.21 | 1.23 | 1.37 | 0.84 | 1.05 |
| Debt to Equity (x) | 0.66 | 0.40 | 0.46 | 0.13 | 0.25 |
| Interest Coverage Ratios (X) | 6.05 | 8.34 | 7.42 | 3.94 | 11.90 |
| Asset Turnover Ratio (%) | 0.43 | 0.42 | 0.71 | 0.70 | 0.88 |
| Inventory Turnover Ratio (X) | 1.85 | 1.85 | 1.31 | 1.15 | 1.08 |
| 3 Yr CAGR Sales (%) | 9.82 | 11.68 | 10.49 | 3.90 | 4.05 |
| 3 Yr CAGR Net Profit (%) | 9.85 | 3.64 | -30.26 | 37.38 | 2.66 |
| P/E (x) | 13.52 | 13.25 | 44.13 | -18.01 | 41.53 |
| P/B (x) | 1.86 | 1.37 | 1.38 | 3.44 | 4.91 |
| EV/EBITDA (x) | 7.80 | 6.07 | 6.31 | 12.95 | 17.83 |
| P/S (x) | 1.20 | 1.01 | 1.01 | 2.29 | 3.26 |
Glenmark Pharmaceuticals Limited has been actively involved in corporate actions. On July 2, 2025, the company informed the exchange about a newspaper publication. Additionally, a newspaper advertisement regarding a postal ballot notice was released on the same day. On July 1, 2025, the company disclosed details of Key Managerial Personnel authorized for determining materiality of events and information to stock exchanges.
The company has also announced dividends regularly. The dividend of Rs 2.50 per share (250%) was announced on May 24, 2024, with an effective date of September 13, 2024. Similar dividends were announced in previous years as well.
The company had announced a bonus issue on January 6, 2005, with a bonus ratio of 1:1 and an ex-bonus date of March 4, 2005.
Glenmark Pharma has also undergone stock splits. On June 11, 2007, the face value was split from Rs 2 to Rs 1, with an ex-split date of September 10, 2007. Another split occurred on July 31, 2003, where the face value was split from Rs 10 to Rs 2, with an ex-split date of October 23, 2003.
A recent Moneycontrol analysis indicates a very bullish sentiment on the stock as of today.
In conclusion, Glenmark Pharma's stock has hit an all-time high, driven by positive financial performance and market sentiment.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
